Adaptive T cells regulate disease tolerance in human malaria

Diana Muñoz Sandoval,[1,2] Florian Bach,[1*] Wiebke Nahrendorf,[1*] Alasdair Ivens,[1,3] Michalina
Mazurczyk,[4] Yrene Themistocleous,[5] Sarah E. Silk,[5] Jordan R. Barrett,[5] Nick J. Edwards,[5] Giorgio
Napolitani,[4] Angela M. Minassian,[5] Simon J. Draper[5] and Philip J. Spence[1,3]

[1]Institute of Immunology and Infection Research, University of Edinburgh, UK.
[2]Instituto de Microbiologia, Universidad San Francisco de Quito, Ecuador.
[3]Centre for Immunity, Infection and Evolution, University of Edinburgh, UK.
[4]MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, UK.
[5]The Jenner Institute, University of Oxford, UK.

* these authors contributed equally
correspondence: philip.spence@ed.ac.uk

impact statement | malaria attenuates T cell activation to increase host fitness

Abstract

Immunity to severe malaria is acquired quickly, operates independently of pathogen load and
represents a highly effective form of disease tolerance. The mechanism that underpins tolerance in
human malaria remains unknown. We developed a re-challenge model of falciparum malaria in
which healthy naive adult volunteers were infected three times over a 12-month period to track the
development of disease tolerance in real-time. We found that parasitaemia triggered a hardwired
emergency myeloid response that led to systemic inflammation, pyrexia and hallmark symptoms of
clinical malaria across the first three infections of life. In contrast, CD4$^+$ T cell activation was quickly
modified to reduce the number and diversity of effector cells upon re-challenge. Crucially, this did
not silence critical helper T cell functions but instead prevented the generation of cytotoxic effectors
associated with autoinflammatory disease. Tolerised hosts were thus able to prevent collateral tissue
damage and injury. Host control of T cell activation can therefore be established after a single
infection and in the absence of anti-parasite immunity. And furthermore, this rapid host adaptation
can protect vital organs to minimise the harm caused by systemic inflammation and sequestration.

Introduction

The epidemiology of human malaria clearly shows that immunity develops in two distinct phases. First, individuals acquire protection against severe life-threatening disease and in areas of high transmission this occurs very quickly (often before 12-months of age) (1-4). Then after many years of exposure protection against clinical malaria is established, which promotes the transition to asymptomatic infection (usually in adolescence) (5). This temporal dissociation between clinical immunity and immunity to severe malaria has led to the assumption that they must be underpinned by different mechanisms of host defense. In agreement, clinical immunity coincides with control of parasite burden (and is therefore supported by mechanisms of host resistance) whereas immunity to severe malaria is acquired independently of pathogen load and is a form of disease tolerance (1). One leading hypothesis suggests that broadly neutralising antibodies that recognise variant surface antigens associated with severe malaria (such as group A/DC8 PfEMP1) could prevent severe disease without affecting total pathogen load (2). In this scenario, immunity to severe malaria would depend upon the rapid production of antibodies that can specifically eliminate pathogenic variants. At present, there is limited evidence that such broad cross-reactivity can be achieved or that neutralising antibodies can be produced within the first year of life to inhibit cytoadherence and reduce sequestration *in vivo* (6). The mechanism that underpins disease tolerance in human malaria therefore remains unclear.

An alternative explanation is that the host response to infection is quickly modified to minimise the harm caused by malaria parasites. It is well known that metabolic adaptations are induced during the blood cycle to increase host fitness (7-9) and control of inflammation might provide an additional path towards disease tolerance (10). In support of this argument, inflammation can be uncoupled from parasite density in children (11) and pathogenic immune responses can be silenced to minimise tissue stress and toxicity in mice (12). Importantly, host control of inflammation as a defense strategy would not rule out a role for variant surface antigens in severe disease. After all, systemic inflammation, tissue damage and hypoxia could create the right conditions for endothelium activation and the selection of pathogenic variants (13). As such, reducing inflammation may minimise the preferential expansion of parasites associated with severe malaria - this would represent a highly effective route to disease tolerance that would not be influenced by parasite strain or genotype.

Host adaptations that are quickly established to reduce disease severity will be hard to identify in an endemic setting due to the difficulty of pinpointing an infant's first infection of life. On the other hand, controlled human malaria infection (CHMI) (14) offers an unparalleled opportunity to investigate mechanisms of disease tolerance. Naive volunteers are inoculated with live and non-attenuated parasites and their response can be tracked throughout infection and convalescence by repeated sampling; pre-infection samples can be collected to provide all-important baseline measurements; and the immune system is exposed to an enormous antigen load at the peak of infection (more than 10^7 parasites per litre of blood) (13). Crucially, adults are more susceptible to severe malaria than children during a first-in-life infection (15, 16) and so we can study the most at-risk group of individuals. We therefore developed a human re-challenge model of falciparum malaria to track the development of disease tolerance in real-time across the first three infections of life.

Results

Malaria does not induce fast-acting mechanisms of host resistance

We developed a human re-challenge model of falciparum malaria in which ten healthy adult
volunteers were infected two times (4-months apart) by intravenous injection of infected red cells;
six volunteers returned for a third infection 8-months later (figure 1A). A blood challenge model was
chosen because it standardises the infectious dose, prolongs the period of blood-stage infection (cf.
mosquito challenge) and removes liver-stage immunity as a possible confounding factor upon re-
challenge (17, 18). Furthermore, volunteers were always inoculated with the same clonal malaria
parasite (3D7) to remove parasite genotype as an infection-dependent variable. Importantly, we
used a recently mosquito-transmitted line (< 3 blood cycles from liver egress) (19) since mosquitoes
have been shown to reset parasite virulence (20). Volunteers attended clinic the day before infection
(baseline), every 12-hours from the day after infection until diagnosis (peak of infection) and then
24- and 48-hours after drug treatment. These frequent visits allowed for regular blood sampling to
construct a detailed longitudinal time-course of each volunteer's response to the first three infections
of life.

We found that pathogen load and the parasite multiplication rate were comparable between the first,
second and third malaria episode (figure 1B-C and supplementary file 1). Whilst epidemiology has
shown that anti-parasite immunity does not develop within this time-frame (1) these data
nevertheless derive from an endemic setting where each infection is caused by a new parasite
genotype. It is remarkable then that in our study (which removes polymorphism as an obstacle to
immunity) we find no evidence that volunteers can limit the replication of parasites they have seen
previously. Epidemiology has also shown that immunity to clinical malaria is slow to develop, and in
most cases is not acquired until adolescence (5). In agreement, we found no significant difference
in the number or severity of adverse events (such as headache, fever and fatigue) between first,
second and third infection (figure 1D-E). Differential blood counts revealed other hallmark symptoms
of clinical malaria, such as lymphopenia and anaemia, were also comparable between infections
(figure 1F and figure 1 - supplement 1). These data thus show that healthy adult volunteers do not
acquire mechanisms of resistance (to reduce parasite burden) and remain susceptible to clinical
malaria in a homologous re-challenge model.

Re-challenge triggers a hardwired emergency myeloid response

The absence of anti-parasite immunity means that any change in the host response to re-challenge
must occur independently of pathogen load. Our model therefore provides the ideal setting in which
to investigate host adaptations that confer disease tolerance. One route to tolerance may be to
reduce systemic inflammation - this correlates with clinical immunity in endemic regions (11) but
whether it also coincides with immunity to severe disease is not known. In human challenge studies
the immune response detected in whole blood at the peak of infection is largely driven by activated
monocytes and neutrophils, which are in transit from the bone marrow (site of activation) (21) to the
spleen (target organ) (22). To capture this acute phase response we used whole blood RNA-
sequencing and DESeq2 to identify differentially expressed genes at diagnosis (relative to baseline)
in first, second and third infection. We found a remarkably similar pattern of interferon-stimulated
type I inflammation regardless of infection number (figure 2 - supplement 1). Furthermore, functional

gene enrichment analysis showed that the hierarchy of GO terms was near-identical between infections (figure 2A). This emergency myeloid response has been extensively described in naive hosts infected with *P. falciparum* (13, 23, 24) and *P. vivax* (Bach *et al.*, under review, preprint available at doi.org/10.1101/2021.03.22.21252810) but it was surprising to see no obvious change upon re-challenge. Nevertheless, by analysing each infection independently it was possible that we were missing important quantitative differences and we therefore performed direct pairwise comparisons between first, second and third infection. Initially, we compared each pre-infection time-point to identify season-dependent shifts in baseline gene expression - we found zero differentially expressed genes between infections (adj p < 0.05 and absolute fold change > 1.5). When we then compared each diagnosis time-point to identify adaptations in the host response we again found zero differentially expressed genes (figure 2B); evidently, the first three infections of life trigger a hardwired emergency response that is not influenced by season or previous exposure.

Nonetheless, host control of inflammation may not be transcriptionally regulated and we therefore directly measured systemic inflammation at protein level using a highly multiplexed custom bead array (39 plasma analytes indicative of inflammation, coagulation, oxidative stress & metabolism). By analysing the concentration of each analyte through time we found many of the prototypical products of monocyte and neutrophil activation (such as CXCL10, IL-1RA & MPO) were significantly increased at diagnosis, together with hallmark cytokines associated with innate lymphoid cell (ILC) or T cell activation (IFNɣ and IL-21) (figure 2C and figure 2 - supplement 2). Surprisingly, our data seemed to suggest that this response was not attenuated but enhanced upon re-challenge. To directly test this hypothesis we fitted a linear mixed-effects model for each analyte, which showed that the major secreted products of interferon-stimulated inflammation were significantly increased in second and third (compared to first) infection (figure 2D). Collectively, these data demonstrate that *P. falciparum* triggers a hardwired emergency myeloid response throughout the first three infections of life. And crucially, we find no evidence that systemic inflammation can be attenuated to quickly establish disease tolerance.

Malaria uncouples T cell activation from systemic inflammation

Our data do not exclude the importance of minimising systemic inflammation to improve clinical outcome but indicate that long-term exposure to parasites is required to restrict an inflammatory myeloid response (12). These data may partially explain why immunity to clinical malaria is not usually established until adolescence. So what other host adaptations could be acquired early in life to promote immunity to severe disease? To answer this question we examined adaptive T cells, which are inherently plastic, proliferative and long-lived, and therefore uniquely placed to quickly and permanently alter the host response to infection. The acute phase response to malaria causes extreme lymphopenia leading to a 30 - 70% loss of circulating T cells at the peak of infection (figure 1 - supplement 1). The majority of these cells are recruited to the inflamed spleen (25) and it is therefore difficult to assess T cell activation and differentiation at diagnosis. Instead, we need to analyse T cell activation after drug treatment when the myeloid response begins to resolve and T cells return to the circulation. At this time-point, analysing T cell phenotypes in whole blood can provide a direct readout of tissue-specific immune responses in human malaria.

Post-treatment blood samples were not available from this cohort of volunteers in their first infection
but were collected 6-days after drug treatment of either their second or third malaria episode. We
therefore had to recruit new malaria-naive controls to provide time-matched post-treatment samples
of first infection and switched to a cross-sectional study design with 11 volunteers infected
contemporaneously (3 first infection, 2 second infection and 6 third infection during the VAC063C
trial) (see methods and supplementary file 1). Six days after drug treatment (designated T6)
lymphopenia had completely resolved and there was no evidence of delayed onset anaemia (figure
3A and figure 3 - supplement 1A). All other clinical symptoms of malaria (inc. fever) also resolved
and markers of systemic inflammation had returned almost entirely to baseline - this was observed
in every volunteer regardless of infection number (figure 3 - supplement 1B). It was therefore a
surprise to find a large transcriptional signature in whole blood at T6, which was equal in size to the
emergency myeloid response captured at diagnosis (figure 3 - supplement 2A). These signatures
did not overlap and instead the differentially expressed genes at T6 had unique functional enrichment
terms relating to cell cycle and nuclear division (figure 3 - supplement 2B-C). Remarkably, this
proliferative burst was only observed in volunteers undergoing their first infection of life (figure 3 -
supplement 3).

Myeloid cells are generally terminally differentiated and do not proliferate after their release from the
bone marrow; it therefore seemed likely that our whole blood RNA-sequencing data were capturing
the return of activated T cells to the circulation. To explore this further we sorted $CD4^+$ T cells with a
naive ($CCR7^{pos}$ $CD45RA^{pos}$), effector / effector memory (EM) ($CCR7^{neg}$ $CD45RA^{neg}$) or regulatory
($CD25^{hi}$ $CD127^{neg}$) phenotype one day before challenge and six days post-treatment. Analysis of the
cell surface markers used for sorting revealed dramatic activation of effector / EM and regulatory
subsets in first infection but not reinfection (figure 3B and figure 3 - supplement 4). These data
suggested that T cell activation and systemic inflammation could be uncoupled in malaria. To directly
test this hypothesis we constructed a pearson correlation matrix and included all plasma analytes
that were significantly up- or downregulated at diagnosis or T6 together with the frequency of
activated effector and regulatory $CD4^+$ T cells (figure 3C). Also included were hallmark symptoms of
clinical malaria such as pyrexia, lymphopenia and anaemia. We found a strong and significant
positive correlation between markers of myeloid cell activation (inc. CXCL10, IL-1RA & TNFRII),
coagulation (D-Dimer) and maximum core temperature ($r > 0.7$ and $p < 0.05$). Moreover, each of
these features negatively correlated with lymphocyte counts and haemoglobin. In contrast, activated
effector and regulatory $CD4^+$ T cells did not correlate with any feature of the acute phase response
(supplementary file 2). The intensity of inflammation therefore scales with clinical symptoms but does
not influence $CD4^+$ T cell activation.

T_H1 polarisation is a unique feature of first infection

Naive adults are highly susceptible to severe malaria (15) and our data clearly show that the unique
feature of their response to infection is fulminant T cell activation. To explore the transcriptional
landscape of activated $CD4^+$ T cells in first infection (compared to third) we undertook RNA-
sequencing on the naive, effector / EM and regulatory subsets that we had sorted during the
VAC063C trial (figure 3 - supplement 4) and used DESeq2 to identify differentially expressed genes
at T6 (versus baseline). As expected, cells with a naive phenotype displayed few transcriptional
changes upon their return to circulation; in contrast, we found almost 6000 differentially expressed
genes in effector / EM $CD4^+$ T cells (adj $p < 0.05$ and > 1.5-fold change). Functional gene enrichment

analysis showed that effector cells were proliferative, metabolically reprogrammed and highly
activated in first infection, upregulating each of the major costimulatory and inhibitory receptors
required to control their fate (figure 4A and figure 4 - supplement 1). Moreover, they specifically
upregulated the signature chemokine receptors and transcription factors associated with T_H1
polarisation (figure 4B). The cytokines IFNɣ and IL-21 were also both strongly induced, which could
indicate that infection stimulates double-producers (26) or that activated follicular helper T cells are
also released from the spleen (figure 4C).

In third infection IFNɣ and IL-21 were once again significantly upregulated at T6 together with TNF
and T_H1-associated chemokine receptors (figure 4B-C). CD4$^+$ T cells are thus clearly responsive to
re-challenge despite the lack of evidence for their activation by flow cytometry (figure 3B). Yet
remarkably, the transcription factors that drive T_H1 differentiation (T-bet and STAT1) were no longer
induced, and neither were the costimulatory molecules or inhibitory receptors observed in first
infection (figure 4A-B). So what modifies CD4$^+$ T cell activation to avert T_H1 polarisation upon re-
challenge? We found no transcriptional evidence that T cells are quiescent or anergic in third
infection and crucially the transcription factors that epigenetically enforce exhaustion were not
upregulated (figure 4A and figure 4 - supplement 2A-B). Furthermore, there was no evidence for
activation induced cell death - this feature was unique to first infection (figure 4 - supplement 2C).
There was also no evidence that effector CD4$^+$ T cells were diverted towards a regulatory fate; for
example, hallmarks of T_R1 differentiation (such as Eomes and IL-10) were absent (figure 4B-C).

An alternative explanation could be suppression by conventional regulatory CD4$^+$ T cells yet our
data show that Tregs simply mirror the response of effector cells. Their activation is tightly co-
regulated (figure 3C) and in first infection Tregs launch a transcriptional programme with remarkable
overlap to that of effectors (e.g. they upregulate all signature T_H1 genes including T-bet) (figure 4D).
In contrast, we could find no transcriptional evidence of Treg activation upon re-challenge. It is well
established that regulatory T cells mimic the transcriptional response of the effector cells they are
required to regulate (27) and this phenomenon is clearly evident in naive hosts. In fact, by
constructing a merged gene ontology network that uses all of the differentially expressed genes
identified in effector / EM and regulatory CD4$^+$ T cells we could show that Tregs do not display any
unique functional terms (figure 4E). We therefore conclude that regulatory T cells are redundant
during reinfection and that their activation is not required because there is no explosive effector
response to keep in check. Instead, it would seem that tolerised hosts launch a specialised adaptive
T cell programme that can maintain cytokine production without causing extensive activation,
proliferation or T_H1 polarisation. Remarkably, we can identify this major shift in the host response in
whole blood (figure 4F) and it will therefore be possible to identify tolerised hosts in an endemic
setting without the need for complex cell isolation protocols.

Tolerance minimises effector T cell heterogeneity

One limitation of bulk RNA-sequencing is that it can not reveal the heterogeneity of an immune
response; this is particularly problematic for CD4$^+$ T cells, which are inherently diverse and plastic.
Furthermore, there is very little power to detect transcriptional changes if only a small proportion of
cells are activated, as seemed to be the case in third infection. We therefore used mass cytometry
to undertake single cell analysis of T cell activation through first and third infection. Importantly, we

designed an antibody panel that would allow us to interrogate every T cell lineage, and examine the
key markers of activation, differentiation and fate (supplementary file 3). We first concatenated all
data (from every volunteer and time-point) and used Uniform Manifold Approximation and Projection
(UMAP) to visualise the phenotypic diversity of T cells across the dataset. We then used FlowSOM
clustering to assign each T cell to one of 49 discrete clusters (figure 5 - supplement 1). As expected
most of the diversity was observed within the non-naive CD4$^+$ and CD8$^+$ T cell subsets (figure 5A).
Tracking the frequency of each cluster through time then resolved dynamic changes in the T cell
compartment (figure 5 - supplement 2 for CD4$^+$ T cells, supplement 3 for CD8$^+$ T cells and
supplement 4 for innate-like T cells). Finally, we performed linear regression on cell count data using
EdgeR to identify the differentially abundant clusters at each time-point relative to baseline (FDR <
0.05 and absolute fold-change > 2).

In first infection eighteen T cell clusters increased in abundance at T6 and all had an activated
phenotype; these were comprised of twelve adaptive and six innate-like clusters. In third infection,
twelve clusters increased in abundance and not one was unique to re-challenge (all were significant
in first infection). Remarkably, we found that diversity was specifically reduced in the adaptive T cell
response with only six adaptive clusters called as significant in third infection. Moreover, of these six
clusters all but one was reduced in size compared to first infection (figure 5B-C). This means that
activated CD4$^+$ T cells dominate the response of naive hosts to malaria whereas in tolerised hosts
the T cell response largely consists of innate-like cells (figure 5D). So how do the phenotypes of
activated CD4$^+$ T cells compare between infections? We observed enormous heterogeneity in first
infection with the expansion of nine distinct CD4$^+$ T cell clusters. There were common traits (such as
expression of the activation marker CD38 and the memory marker CD45RO) and most had an
effector (CCR7^{neg}) phenotype but many clusters displayed unusual or unexpected features (figure
5E). As one example, the largest pool of activated CD4$^+$ T cells had a highly differentiated CD27^{neg}
CX3CR1^{pos} cytotoxic phenotype, which is usually observed in autoinflammatory conditions (not
infectious disease) (28, 29). Notably, the upregulation of perforin and granzyme B could be seen in
CD4$^+$ T cells by RNA-sequencing (figure 4C) and there were many other areas of concordance
between the datasets. Most importantly, our protein data confirmed that effector CD4$^+$ T cells were
highly activated (CD28^{hi} PD1^{hi}), T_H1 polarised (T-bet^{hi}), proliferative (Ki67^{hi}) and accompanied by the
activation of Foxp3^{hi} CD39^{hi} T-bet$^+$ regulatory T cells.

In contrast, the unusual CD4$^+$ T cell phenotypes observed in naive hosts were essentially absent in
third infection and there was no expansion of activated Tregs (figure 5C). Instead, the majority of
expanded CD4$^+$ T cells belonged to a single cluster with an apparently benign effector phenotype
(ICOS^{neg} Ki67^{neg} T-bet^{lo} Eomes^{neg}) (figure 5E). These cells are clearly activated (CD38^{hi} Bcl2^{lo}) and
had already increased in abundance at diagnosis (figure 5 - supplement 2). A faster response may
indicate that these are malaria-specific memory cells. Furthermore, as the dominant activated cluster
these CD4$^+$ T cells are likely to be responsible for most of the transcriptional changes in the effector
/ EM subset in third infection, including cytokine production (figure 5D and figure 4C). To validate
these phenotypic observations we used *limma* to model differential marker expression through time
(figure 5 - supplement 5). This analysis confirmed widespread upregulation of activation and
differentiation markers in effector / effector memory and regulatory T cells in first infection but an
attenuated response to re-challenge (figure 5 - supplement 5 and 6).

Collectively, these data show that tolerance leads to a smaller and less diverse adaptive T cell response. Although at first glance this may seem counterintuitive we argue that this is a more proportional host response designed to support the development of humoral immunity (long-term goal) whilst providing short-term protection against collateral damage. After all, it is essential to prioritise host fitness when infected with a pathogen that can not be cleared and the functionally diverse CD4+ T cell response triggered in naive hosts does not appear to be beneficial (there is no evidence for reduced pathogen load or improved clinical outcome during a first-in-life infection in this study or endemic settings (30)). Moreover, the frequency of CD38hi CD4+ T cells in third infection is not small (it is comparable to typhoid fever (31)) and effector cells have retained critical helper functions (IFNɣ and IL-21). It therefore appears that the adaptive response of a naive host is atypical leading to the activation of 20 - 40% of every T cell in circulation (figure 5F) and the generation of cytotoxic effectors previously associated with immune-mediated disease.

Controlling T cell activation protects host tissues

To directly test whether T cell activation in first infection could be pathological we measured biomarkers of collateral tissue damage, a common histological feature of severe malaria. The blood-stage of infection frequently causes liver injury in naive hosts (32-34) and auto-aggressive human T cells can directly kill hepatocytes through TCR-independent mechanisms (35) - we therefore measured alanine aminotransferase (ALT) to provide a readout of hepatocellular death in our cohort. In first infection, two out of three volunteers had abnormal ALT (more than the upper limit of the reference range) when activated T cells were released from inflamed tissues at T6 (figure 6A). This was accompanied by increased gamma-glutamyl transferase (GGT) and aspartate aminotransferase (AST) leading to moderate or severe adverse events in both volunteers. In contrast, there was little evidence of any deviation from baseline in liver function tests after re-challenge. A meaningful statistical comparison between naive and tolerised hosts was not possible due to the small sample size in first infection (n = 3) and we therefore performed a meta-analysis using a previously published surrogate dataset (33). Specifically, we examined post-treatment ALT measurements in almost 100 volunteers experiencing a first-in-life infection as part of a human challenge study. Importantly, we only included CHMI trials that were directly comparable to our own re-challenge study - that is to say that the same clonal parasite genotype was used (3D7 or the parental NF54 line); parasites had recently been transmitted through the vector; and the same study end-points were applied (treatment at around 10,000 parasites ml^{-1}) (figure 6B). Remarkably, we found that the prevalence of abnormal ALT was reduced from 75% during first infection to 25% upon re-challenge (figure 6C). And in those rare cases where ALT was increased in second or third infection adverse events were mild (not moderate or severe) even though pathogen load was increased (figure 6B). These data thus show that the risk of tissue damage and injury can be significantly reduced in the absence of parasite control. Here then is *in vivo* evidence that long-lived mechanisms of disease tolerance operate in human malaria and can be acquired after a single infection. Moreover, protection does not require the attenuation of systemic inflammation but instead coincides with host control of T cell activation.

Discussion

It has long been recognised that immunity to severe malaria is acquired early in life, offers protection against all manifestations of severe disease and usually precedes clinical immunity (the transition to asymptomatic infection) by more than a decade (2-5). We also know that immunity to severe malaria does not require improved parasite control (1) and is thus underpinned by acquired mechanisms of disease tolerance. This is an important distinction to make if we want to understand how to reduce malaria mortality. Host control of inflammation could provide a rapid route to disease tolerance but our data show that malaria parasites trigger a hardwired emergency myeloid response across the first three infections of life. In contrast, CD4+ T cell activation is quickly modified to limit the number and diversity of effector cells. Our pilot data from a re-challenge model using *P. vivax* shows the same attenuation of CD4+ T cells after a single infection (figure 6 - supplement 1). Exposure-dependent control of T cell activation therefore occurs independently of parasite species, pathogen load and systemic inflammation. Importantly, tolerance does not silence the adaptive response to re-challenge (cytokine-producing T-bet^{lo} EM CD4+ T cells are re-activated) but avoids cell fates associated with collateral damage and autoinflammatory disease. Whilst we can't directly show that this reduces the risk of severe malaria in a human challenge model the epidemiology of *P. falciparum* clearly shows that disease tolerance can be established within the first three infections of life (1, 36).

So how is the adaptive T cell response to malaria modified so quickly and so dramatically? One possibility is that infection initiates heritable epigenetic programmes that reduce T cell responsiveness. Our data do not provide transcriptional evidence of anergy or exhaustion but this hypothesis needs to be directly tested. An alternative explanation could be the clonal deletion of activated T cells during first infection reducing the number of malaria-specific clones available for re-challenge. Or perhaps, tolerance requires no T cell-intrinsic modifications but an attenuation of the antigen presenting capacity of the spleen. After all, hemozoin-loaded dendritic cells and macrophages have a reduced capacity to stimulate T cell proliferation *in vitro* (37). Long-term modifications to the tissue environment (12) (including the presence of malaria-specific antibodies) may also impact T cell differentation and block the development of terminally differentiated pathogenic effectors. Nonetheless, the activation of T-bet^{lo} EM CD4+ T cells (and production of IFNɣ and IL-21) may be sufficient to support the gradual acquisition of humoral immunity in tolerised hosts. Perhaps then we are asking the wrong question and should instead examine how malaria can drive such extensive and diverse T cell activation in a naive host.

One possibility is that infection leads to widespread bystander activation of CD4+ T cells that do not recognise malaria antigens. These could be pre-existing memory cells, which can be activated in the absence of TCR signals and costimulation (38, 39). This would certainly explain the speed, magnitude and heterogeneity of T cell activation in our naive volunteers. And furthermore, it may explain the increased susceptibility of adults to severe disease during a first-in-life infection (they have a far larger memory pool than infants and children). Malaria may also cause activation of autoreactive T cells, which would need to be quickly suppressed by activated Tregs in first infection. Central tolerance (which deletes autoreactive clones in the thymus) is only partially effective and there is enormous degeneracy in TCR reactivity (40). Systemic infection with a pathogen carrying more than 5000 protein-coding genes may therefore lead to considerable cross-reactivity between parasite and host. Indeed, hypergammaglobulinemia and autoantibody production are known

features of human malaria (41, 42). We therefore propose that bystander and cross-reactive T cells may account for the majority of T cell activation in naive hosts. And because they can be activated via TCR-independent or low affinity interactions (39, 43) it might be possible to specifically silence their pathogenic response without impeding re-activation of high affinity malaria-specific clones. Support for this idea comes from the observation that *P. chabaudi* triggers massive polyclonal activation of CD4$^+$ T cells in first infection but not reinfection in mice (44).

Importantly, we have shown that parasite species regulates T cell activation in naive hosts - *P. falciparum* drives a bigger CD4$^+$ T cell response with more functional diversity than *P. vivax* even though they trigger a near-identical myeloid response (Bach *et al*., under review, preprint available at doi.org/10.1101/2021.03.22.21252810). A combination of increased sequestration and T cell activation could therefore underpin the increased virulence of *P. falciparum*. This could explain why large multi-centre genome-wide association studies have failed to identify SNPs in immune genes that can predict susceptibility to severe malaria (45). Variation in human T cells is almost exclusively driven by non-heritable factors (46). And it may also explain how immunity to severe malaria can be acquired so quickly. Exposure-dependent control of T cell activation could reduce tissue damage, endothelium activation and toxicity to minimise the harm caused by cytoadherence. Crucially, our data show that a single asymptomatic drug-cured infection is sufficient to silence pathogenic T cells. Interventions that reduce the risk of clinical malaria but don't completely eliminate infection (such as mass drug administration) may thus induce long-lived mechanisms of disease tolerance in endemic settings.

Acknowledgements

We thank Paul Sopp for *ex vivo* T cell sorting during the VAC063 trial. Flow sorting and CyTOF data were generated within the flow and mass cytometry facilities at the Weatherall Institute of Molecular Medicine (University of Oxford), which are supported by MRC Human Immunology Unit core funding (MC_UU_00008) and the Oxford Single Cell Biology Consortium (OSCBC). T cell RNAseq libraries were prepared and sequenced by the Edinburgh Clinical Research Facility at the University of Edinburgh, which receives financial support from NHS Research Scotland (NRS). Whole blood RNAseq libraries were prepared and sequenced by Edinburgh Genomics, which is supported through core grants from NERC (R8/H10/56), MRC UK (MR/K001744/1) and BBSRC (BB/J004243/1). We would like to extend our thanks to the VAC063 and VAC069 clinical and laboratory teams for assistance, and to all of the volunteers who participated in this study.

Funding

The VAC063 and VAC063C trials were supported in part by the Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development (USAID) under the terms of the Malaria Vaccine Development Program (MVDP) contract AID-OAA-C-15-00071, for which Leidos, Inc. is the prime contractor. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the USAID. The clinical trial was also supported in part by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The VAC069 trial was supported by funding from the European Union's Horizon 2020 research and innovation programme under grant agreement for MultiViVax (number 733073). DMS is the recipient of a Darwin Trust of Edinburgh PhD studentship. FB is the recipient of a Wellcome Trust PhD studentship (grant no. 203764/Z/16/Z). SJD held a Wellcome Trust Senior Fellowship (grant no. 106917/Z/15/Z) and is a Jenner Investigator. And PJS is the recipient of a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant no. 107668/Z/15/Z).

Data availability

All RNAseq data (whole blood and sorted T cell subsets) have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO SuperSeries accession number GSE172481. CyTOF (mass cytometry) data have been deposited at flowrepository.org and can be accessed through experiment numbers FR-FCM-Z47Z (VAC063C); FR-FCM-Z3HA (VAC069A); and FR-FCM-Z465 (VAC069B).

The authors have no conflict of interest to declare and the funders had no role in study design, data interpretation or the decision to submit the work for publication.

Figure 1 I Malaria does not induce fast-acting mechanisms of host resistance. (**A**) Healthy malaria-naive adults were infected up to three times with *P. falciparum* (clone 3D7) by direct blood challenge. Repeated sampling before, during and after each infection allowed us to track the development of disease tolerance in real-time. (**B**) Parasite growth curves for first, second and third infection (each line represents a volunteer and lines are colour-coded by infection number). Parasite density in whole blood was measured by qPCR every 12-hours - the grey box represents the lower limit of quantification (20 parasites*ml^{-1}) and the treatment threshold of 10,000 parasites*ml^{-1} is denoted by the pink line. (**C**) Maximum parasite density during first, second and third infection; each dot represents a volunteer and bars show the median. No statistically significant difference between infections was observed (Kruskal-Wallis test p = 0.9054). (**D-F**) Clinical symptoms of malaria were recorded on diary cards (self-reporting) or during clinic visits; these adverse events were graded as mild, moderate, or severe (see methods). (D) Number of adverse events at each time-point throughout infection and up to 48-hours after treatment (each line represents a volunteer and lines are colour-coded by infection number). (E) Severity of adverse events in the 48-hours before and after diagnosis in first, second and third infection. (F) Frequency and severity of lymphopenia, pyrexia and anaemia during first, second and third infection. No statistically significant difference between infections was observed for any adverse event (Kruskal-Wallis test using a significance threshold of 5%). In (B-F) sample size (n) is 10 (for first and second infection) and 6 (third infection).

Figure 2 | Re-challenge triggers a hardwired emergency myeloid response. (**A**) RNA-sequencing was used to identify differentially expressed genes in whole blood at diagnosis versus baseline (adj $p < 0.05$ and > 1.5 fold-change). ClueGO was then used for functional gene enrichment analysis and placed significant GO terms into functional groups by relatedness (see methods). Shown are the leading GO terms from 15 non-redundant groups with the lowest adj p value in first infection. We plotted the same GO terms in second and third infection. Note that each infection was analysed independently. (**B**) Radar plots (or 3-way volcano plots) show the number of differentially expressed genes in whole blood between infections. Direct pairwise comparisons between second and first, third and first and third and second infection were performed - the left plot compares all baseline samples and the right plot the diagnosis time-points. Dashed lines represent the centre-point for each volcano plot and the position of each dot relative to this line shows up- or downregulation. There were no differentially expressed genes in any of the six pairwise comparisons (adj $p < 0.05$ and > 1.5 fold-change). (**C**) 39 plasma analytes were quantified before and during each infection using a highly multiplexed bead-based array. The log2 fold-change of each analyte is shown relative to baseline on day 6 and 8 post-challenge (c6 and c8, respectively) and at diagnosis. Analytes are ordered by log2 fold-change in second infection. (**D**) Mixed-effects modelling was used to identify plasma analytes that vary significantly between infections at diagnosis. Multiple test correction was performed using the Benjamini-Hochberg method and analytes that were significant in both second and third infection (versus first infection) are shown (adj $p < 0.05$). Box (median and IQR) and whisker (1.5x upper or lower IQR) plots are shown with outliers as dots. In (A-B) n = 10 (first infection), 9 (second infection) and 6 (third infection). v1040 was excluded from RNA-sequencing analysis in second infection because their baseline sample failed QC. In (C-D) n = 9 (first and second infection) and 5 (third infection). v1040 was excluded from plasma analysis because all samples failed QC (see methods).

figure three

Figure 3 l Malaria uncouples T cell activation from systemic inflammation. (**A**) Lymphocytes were quantified in whole blood 6-days post-challenge (c6), at diagnosis, 6-days after treatment (T6) and at two memory time-points (45 and 90-days post-challenge). Counts were normalised to baseline measurements (taken one day before challenge). Each line represents a volunteer and lines are colour-coded by infection number. A statistically significant deviation from baseline was observed only at diagnosis (Wilcoxon matched-pairs signed rank test, *** $p < 0.001$). (**B**) The percentage of activated CD38^{hi} CD4$^+$ T cells was analysed by flow cytometry at baseline (grey dots) and T6 (coloured dots). Data are shown for naive, effector / effector memory (EM) and regulatory subsets in volunteers undergoing their first, second or third infection of life (see figure 3 - supplement 4 for gating strategies). (**C**) Pearson correlation matrix of the log2 transformed fold-change of lymphocytes, haemoglobin and differentially abundant plasma analytes. Fold-change was calculated either at diagnosis or T6 (relative to baseline) according to when this was largest for each feature. Also included is maximum parasite density, maximum core temperature (up to 48-hours post-treatment) and the percentage of activated effector and regulatory CD4$^+$ T cells (at T6). The order of features was determined by hierarchical clustering. In (A-B) n = 11 (3 first infection, 2 second infection and 6 third infection) and in (C) n = 10 (3 first infection, 2 second infection and 5 third infection). v1040 was excluded from plasma analysis because all samples failed QC.

sorted effector / EM CD4⁺ T cells

A
activation
CD38
MKI67
[TIM3]
HLA−DRA
CTLA4
ICOS
KLRG1
LAG3
[PD1]
LAIR1
MR1
GPR174
BCL2

exhaustion
TOX2
NR4A1
TOX
[TCF1]

first   third

B
fate
[TBET]
STAT1
BCL6
EOMES
GATA3
STAT6
STAT4
STAT3
RORC
RORA

chemokine R
CCR5
CXCR6
CXCR3
CXCR5
CXCR4

first   third

log2FC
2
0
−2

C   effector molecules
log2FC
IL21
IFNG
GZMA
PRF1
GZMB
TNF
IL10
2
1.5
1
0.5

■ first infection
■ third infection

sorted regulatory T cells

D
activation & suppression
[TBET]
CD38
MKI67
CXCR3
[TIM3]
CCR5
GZMB
LAG3
ICOS
STAT1
CTLA4
[PDL2]
PRF1
IL2RA
FOXP3
IL10
GZMA
[PDL1]
[HELIOS]
BCL2

first   third

log2FC
2
0
−2

E

regulation of cellular response to stress

interleukin-1-mediated signaling pathway

T cell activation

gene silencing

receptor ligand activity

cellular response to cytokine stimulus

nuclear division

oxidative phosphorylation

chromatin remodeling

● shared GO term
● enriched in effector / EM CD4⁺ T cells
● enriched in regulatory T cells

whole blood

F
first infection   third infection
MKI67
IL21
IFNG
CTLA4
CD38
CCR5
[PD1]
CXCR6
LAG3
CXCR3
[TIM3]
[TBET]
BCL2
STAT1

diagnosis T6   diagnosis T6

log2FC
5
0
−5

figure four

Figure 4 | T_H1 polarisation is a unique feature of first infection. (**A-C**) During the VAC063C study
RNA-sequencing was used to identify differentially expressed genes in effector / effector memory
(EM) CD4$^+$ T cells 6-days after parasite clearance (T6 versus baseline) in first and third infection (adj
p < 0.05 and > 1.5 fold-change). Heatmaps show the log2 fold-change of (A) markers of T cell
activation and exhaustion and (B) the master transcription factors that shape T cell fate (plus
associated chemokine receptors). The stacked circular bar chart in (C) shows the log2 fold-change
of cytokines and cytotoxic effectors upregulated in first or third infection. Note that *IL10* is not
differentially expressed in either infection. (**D**) RNA-sequencing was used to identify differentially
expressed genes in regulatory CD4$^+$ T cells at T6 (versus baseline) in first and third infection (adj p
< 0.05 and > 1.5 fold-change). Shown are markers of Treg activation and differentiation plus key
suppressor molecules. (**E**) Differentially expressed genes in effector / EM and regulatory CD4$^+$ T cells
were combined for GO analysis of T6 in first infection. ClueGO was used to construct a merged
functional gene ontology network. Each node represents a GO term and nodes are coloured
according to whether their associated genes were majoritively (> 60%) derived from effector or
regulatory cells. GO terms that were shared between T cell subsets are coloured grey - nine leading
GO terms (each from a unique functional group) that were shared are labelled (see methods). (**F**)
RNA-sequencing was used to identify differentially expressed genes in whole blood at diagnosis and
T6 (relative to baseline) in first and third infection (adj p < 0.05 and > 1.5 fold-change). Signature
genes of T cell activation, T_H1 differentation and cytokine production are shown. In (A-E) n = 2 or 3
for first infection (T6 and baseline, respectively) and 6 for third infection. v313 was excluded at T6
because this sample failed QC. In (F) n = 3 for first infection and 6 for third infection. Square brackets
indicate that common gene names were used.

A

memory CD4

naive CD4

naive CD8

activated CD4

MAIT

terminally
differentiated
effectors

gamma delta

B

significant clusters first infection

significant clusters third infection

C

cluster	frequency at T6 (% total T cells)
activated CD161^pos gamma delta	
activated MAIT	
activated CX3CR1^pos CD161^pos gamma delta	
activated CD27^neg CX3CR1^pos cytotoxic EM CD4	
activated CTLA4^hi EM CD4	
activated EM CD4	
activated CD27^neg EM CD4	
activated ICOS^pos CM CD4	
activated CD161^pos EM CD4	
activated CX3CR1^pos EM CD8	
activated T-bet^lo EM CD4	
activated HLA-DR^pos gamma delta	
activated Treg	
activated granzyme B^neg EM CD8	
activated Foxp3^pos CM CD4	
activated CX3CR1^pos NK T TEMRA	
activated CD27^neg EM CD8	
activated double negative	

frequency at T6 (% total T cells)

5   4   3   2   1   1   2   3   4   5

D

first infection

NKT

γδ

MAIT

CD8

Treg

CD4

third infection

NKT

DN

γδ

MAIT

CD8

CD4

E

cluster | significant

■ first infection only
■ first & third infection

normalised marker expression

0   0.5   1

CD4 CD8 Vδ2 Vα7.2 CD38 HLA-DR ICOS CD28 PD1 CD95 Bcl2 CD27 perforin granzyme B T-bet Eomes CTLA4 Ki67 CD127 CD56 CD161 CD49d CD25 Foxp3 CD39 CX3CR1 CD57 CD45RA CD45RO CCR7

F

baseline | diagnosis | T6 | memory

activation (% total T cells)

v313 v315 v320 v1039 v1040 v1061 v1068 v1075 v6032

first infection

third infection

figure five

Figure 5 I Tolerance minimises effector T cell heterogeneity. Whole blood was preserved within 30-
minutes of blood draw at baseline, diagnosis, T6 and 45-days post-challenge (memory time-point)
during the VAC063C study. Samples were stained with a T cell focussed antibody panel (see
supplementary file 3) and acquired on a Helios mass cytometer. After exclusion of normalisation
beads and doublets we gated on CD45^{pos} CD3^{pos} T cells for UMAP projections and FlowSOM
clustering. (**A**) Data from all volunteers and time-points was concatenated to generate a UMAP
projection showing the global structure of our dataset. FlowSOM identified 49 discrete T cell clusters
and each is given a unique colour. The major T cell subsets are labelled according to expression of
lineage, memory and activation markers. (**B**) UMAP projection showing the T cell clusters that are
differentially abundant at T6 in first (left) and third infection (right) (FDR < 0.05 and > 2 fold-change).
Clusters that are not significant are shown in black. (**C**) The mean frequency of each T cell cluster
that is differentially abundant at T6 in first and/or third infection is shown as a proportion of all CD45^{pos}
CD3^{pos} T cells. (**D**) Pies show the relative size of each differentially abundant cluster at T6 in first
(top) and third (bottom) infection. (**E**) Heatmap showing the normalised median expression values
of all markers used for clustering in each of the 18 T cell clusters that were differentially abundant at
T6. Colour codes to the left of the heatmap indicate cluster identity and show whether clusters were
significant in first infection or first and third infection. Note that no cluster was unique to third infection.
(**F**) Stacked bar chart showing the frequency of activated (CD38^{hi} Bcl2^{lo}) T cell clusters at each time-
point. In (A-F) n = 3 for first infection and 6 for third infection.

A

C

| naive | severe | moderate | mild | | normal |
| tolerised | mild | | normal | | |

73.5% (naive mild/moderate/severe), 26.5% (naive normal)

25% (tolerised mild), 75% (tolerised normal)

p = 0.003968

— severe — moderate — mild — normal

B

	data source	number of volunteers	abnormal ALT [b]	severity			peak parasite density [c]
				mild	moderate	severe	
naive	Reuling *et al.* [a]	95	70	40	16	14	
	VAC063C	3	2	0	0	2	
	Total	**98**	**72**	**40**	**16**	**16**	**17,587**

| **tolerised** | VAC063C | **8** | **2** | **2** | **0** | **0** | **36,630** |

[a] studies: EHMI-3, LSA-3, EHMI-8B, EHMI-9, ZonMw2, TIP5 and CHMI-trans1
[b] plasma concentration exceeds the upper limit of the reference range
[c] weighted mean number of parasites per ml whole blood

figure six

Figure 6 | Controlling T cell activation protects host tissues. (**A**) Blood chemistry measured the concentration of alanine aminotransferase (ALT) throughout infection and convalescence in the VAC063C study (baseline, 6-days post challenge (c6), diagnosis, 6 to 18-days after treatment (T6-T18) and 45/90-days post-challenge (memory time-point 1 and 2, respectively)). Each line represents one volunteer and lines are colour-coded by infection number. (**B**) A surrogate dataset from Reuling *et al*. (33) was used to extract information on the frequency and severity of abnormal ALT during a first-in-life infection (up to 6-days post-treatment). All volunteers were infected with *P. falciparum* (3D7 or NF54) as part of a CHMI trial that used equivalent end-points to our own study (see methods). In every case, abnormal ALT was scored using the same adaptation of the WHO adverse event grading system. Data from 95 volunteers in Reuling *et al*. and the 3 first infection volunteers in VAC063C were pooled for analysis. (**C**) Frequency and severity of liver injury during first infection (naive hosts) versus re-challenge (tolerised hosts). Barnard's test was used to statistically determine whether an abnormal ALT reading was more prevalent during a first-in-life infection compared to second or third infection (a p value below 0.05 was considered significant). In (A) n = 11 (3 first infection, 2 second infection and 6 third infection) and in (B-C) n = 98 (first infection) and 8 (re-challenge).

Methods

Clinical trial design

All volunteers were healthy, malaria naive adults aged between 18 and 50 years and were enrolled
in up to three CHMI studies - VAC063A (November 2017), VAC063B (March 2018) and VAC063C
(November 2018). The VAC063 protocol encompassed VAC063A and VAC063B, and was an open
label, non-randomised phase I/IIa clinical trial evaluating vaccine efficacy of the recombinant blood-
stage malaria protein RH5.1 in AS01$_B$ adjuvant (GSK) (47). The VAC063C trial was designed to
investigate the durability of any protective anti-parasite immunity measured in control (non-
vaccinated) volunteers upon homologous re-challenge (Themistocleous Y *et al.*, in preparation). We
collected and analysed whole blood samples from 8 control volunteers in VAC063A (all receiving
their first infection), 10 control volunteers in VAC063B (8 receiving their second infection and 2 their
first infection) and 11 control volunteers in VAC063C (6 receiving their third infection, 2 receiving
their second infection and 3 their first infection) (refer to supplementary file 1). The VAC063 and
VAC063C trials were sponsored by the University of Oxford. VAC063 received ethical approval from
the UK NHS Research Ethics Service (Oxfordshire Research Ethics Committee A, reference
16/SC/0345) and was registered on ClinicalTrials.gov (reference NCT02927145). VAC063C
received ethical approval from the UK NHS Research Ethics Service (South Central - Oxford A,
reference 18/SC/0521) and was also registered on ClinicalTrials.gov (reference NCT03906474). All
CHMI studies were conducted in the UK at the Centre for Vaccinology and Tropical Medicine
(University of Oxford) and were conducted according to the principles of the current revision of the
Declaration of Helsinki 2008 and in full conformity with the ICH Guidelines for Good Clinical Practice.
Volunteers signed written consent forms and consent was checked prior to each CHMI. Details of
volunteer recruitment, consent, inclusion/exclusion criteria and group allocation can be found in
Minassian *et al*. (47).

In each CHMI study, all volunteers were infected by direct intravenous inoculation of *P. falciparum*
(clone 3D7) blood-stage parasites. The inoculum was thawed and prepared under strict aseptic
conditions exactly as described (47, 48) and volunteers received between 452 and 857 infected red
cells in a total volume of 5 ml normal saline. Starting one day after infection volunteers attended
clinic for assessment and blood sampling every 12-hours, and parasite density was measured in
real time by qPCR (target gene = 18S ribosomal RNA). In VAC063A thick blood films were also
evaluated at each time-point by experienced microscopists and diagnosis required volunteers to fulfil
two out of three criteria: a positive thick blood film (one viable parasite in 200 fields) and/or qPCR
data showing at least 500 parasites per ml and/or symptoms consistent with malaria. In VAC063B
and C microscopy was removed as a diagnostic tool to reduce the number of volunteers diagnosed
prematurely without impacting volunteer safety. The new criteria for diagnosis were: asymptomatic
with any available qPCR result above 10,000 parasites per ml or symptomatic with any available
qPCR data above 5000 parasites per ml. At diagnosis volunteers were treated with artemether and
lumefantrine (Riamet) except in cases where its use was contraindicated and atovaquone and
proguanil (Malarone) were given instead. In our analysis, we refer to the blood-draw immediately
before drug-treatment as the diagnosis time-point.

Clinical symptoms of malaria (pyrexia, malaise, fatigue, arthralgia, back pain, headache, myalgia,
chills, rigor, sweats, headache, nausea, vomiting and diarrhoea) were either recorded by the

volunteers on diary cards or during clinic visits. All symptoms were recorded as adverse events and assigned a severity score: 0 - absent; 1 - transient or mild discomfort (no medical intervention required); 2 - mild to moderate limitation in activity (no or minimal medical intervention required); 3 - severe limitation in activity requiring assistance (may require medical intervention). Pyrexia was scored as follows: absent (≤ 37.5°C), mild (37.6 - 38.2°C), moderate (38.3 - 38.9°C) and severe (≥ 39°C). In addition, full blood counts and blood chemistry were evaluated at the Churchill and John Radcliffe Hospital in Oxford providing 5-part differential white cell counts and quantification of electrolytes, urea, creatinine, bilirubin, alanine aminotransferase (ALT), alkaline phosphatase (ALP) and albumin.

Meta-analysis of liver injury

A surrogate dataset from Reuling *et al.* (33) was used to assess the risk of liver injury during a first-in-life infection compared to re-challenge. We extracted data from every CHMI study that used the 3D7 *P. falciparum* clone (or its parental NF54 line), initiated infection via mosquito bite or direct blood challenge and that had a treatment threshold based on thick smear positivity (estimated to be at least 5,000 parasites per ml). This produced data for 95 volunteers across 7 CHMI studies. Notably, Reuling *et al.* used longitudinal data to show that liver function test (LFT) abnormalities peaked up to 6-days post-treatment in line with our own T6 time-point. And furthermore, in every CHMI study (including our own) LFT abnormalities were graded using the same adaptation of the WHO adverse event grading system. An LFT reading > 1.0 but < 2.5 times the upper limit of normal was graded as mild; a reading > 2.5 but < 5.0 times the upper limit was graded moderate; and a reading > 5.0 the upper limit was graded severe. For ALT, the upper limit of normal was 35 or 45 units per litre for female and male volunteers, respectively. Data from the 95 volunteers in Reuling *et al.* and the 3 primary controls in our VAC063C study were pooled for analysis and we calculated a weighted peak parasite density across the entire cohort by using **a**, the mean number of parasites per ml and **b**, the number of volunteers in each of the 8 CHMI studies. To statistically test whether an abnormal ALT reading was more prevalent in the 98 volunteers experiencing their first malaria infection compared to the 8 volunteers undergoing re-challenge (either second or third infection) we used Barnard's test, which examines the association of two independent categorical variables in a 2x2 contingency table. A p value below 0.05 was considered significant.

Processing whole blood for RNA and plasma

Venous blood was drawn into K_2EDTA-coated vacutainers (Becton Dickinson #367835). To preserve RNA for whole blood transcriptome analysis 1 ml of blood was mixed thoroughly with 2 ml Tempus reagent (ThermoFisher #4342792) and samples were stored at -80°C. Note that no more than 2-hours passed between blood draw and RNA preservation. To obtain platelet-depleted plasma 3 ml of blood was divided into two 2 ml Eppendorf tubes and centrifuged at 1,000 xg for 10-minutes at 4°C to pellet cellular components. Working on ice, plasma was then carefully transferred to a new tube and spun again – this time at 2,000 xg for 15-minutes at 4°C to pellet platelets. Cell-free, platelet-depleted plasma was then aliquoted into new tubes, snap frozen on dry ice and stored at -80°C.

Whole blood RNA-sequencing

Whole blood RNA was extracted using the Tempus Spin RNA isolation reagent kit (ThermoFisher #4380204) according to the manufacturer's instructions. To account for the reduced starting volume and to maintain Tempus stabilizing reagent at the correct final concentration we added just 1 ml PBS to each sample after thawing. Diluted samples were then centrifuged at 3000 xg for 30-minutes at 4°C to pellet nucleic acids. Pellets were resuspended in RNA purification resuspension solution and centrifuged on a silica column to remove non-nucleic acid contaminants. After washing, the column was incubated for 2-minutes at 70°C before eluting nucleic acids. 40 μl eluate was then subjected to DNA digestion using the RNA Clean and Concentrator-5 kit (Zymo Research #R1013). Purified RNA was eluted in 30 μl DNAse/RNAse-free water, quantified using a Qubit Fluorometer (HS RNA assay kit, ThermoFisher #Q32852) and RNA integrity assessed using an Agilent Bioanalyzer 2100 (RNA 6000 nano kit Agilent #5067-1511). The average RNA integrity number (RIN) was 9 (98% of samples > 8, lowest RIN 7). Libraries were prepared by Edinburgh Genomics (Edinburgh, UK) using the TruSeq Stranded mRNA library prep kit (Illumina #20020595). Stranded library preparation allows transcript expression to be estimated more accurately; in particular it is more effective in quantifying anti-sense gene expression, properly assigning transcripts to putative coding genes and to resolve ambiguity in reads from overlapping genes. Libraries were sequenced using the NovaSeq 6,000 Illumina platform yielding 50 bp paired end (PE) reads. These short reads are sufficient to accurately capture gene expression thanks to the well annotated human transcriptome. The average number of reads per sample passing QC across all samples was 8.45×10^{7}.

Data analysis of whole blood RNA-sequencing

Quality and content of FASTQ files, which contain raw PE sequencing reads, were assessed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). A single sample (volunteer 1040 baseline second infection) failed quality control and we therefore excluded all RNAseq data from this volunteer's second infection from our analysis. TruSeq primer sequences were removed using cutadapt v1.9, reads were aligned to the Ensembl release 96 Homo sapiens transcript set with bowtie2 v2.2.7 (49) (parameters: —very-sensitive -p 30 —no-mixed —no-discordant —no-unal) and reads that mapped to globin transcripts were discarded (on average 11.7% of mapped reads, range 1.6 – 38.1%). We opted for bioinformatic globin depletion as it is highly sensitive and reproducible (50) whereas depleting globin during RNA preparation can compromise the amount and quality of RNA recovered (51). Following these steps, the average alignment rate to the human transcriptome across all samples was 88%. A matrix of normalised counts for each transcript was obtained from sorted, indexed bam files using samtools idxstats (http://www.htslib.org/doc/samtools.html). Transcript counts were imported into the R/Bioconductor environment (v3.6) and differential gene expression analyses (pairwise group comparisons) performed using functions within the DESeq2 package (52). lfcShrink was applied to the output of each pairwise comparison (type normal). Lists of differentially expressed transcripts were analysed using R (v3.6) - non-coding transcripts were removed and multiple transcripts annotated to the same gene were consolidated by keeping the transcript with the highest absolute fold-change. Only protein-coding transcripts with an adjusted p value (adj p) < 0.05 and a fold-change > 1.5 were considered differentially expressed. Radar plots and heatmaps were generated using the *ggplot2* package (53). The genelists used for cell cycle analysis were manually compiled from published datasets (54, 55) and we allocated genes to a single phase based on cell cycle transcriptional network analysis (56, 57).

Flow-sorting CD4$^+$ T cells

We flow-sorted CD4$^+$ T cell subsets for *ex vivo* RNA-sequencing from 3 ml whole blood collected in K$_2$EDTA Vacutainers. After red cell lysis (erythrocyte lysis buffer, ebioscience #00-4300-54) leukocytes were washed in flow buffer (PBS supplemented with 2% fetal bovine serum (FBS Performance Plus, ThermoFisher #16000044, heat inactivated & filtered 0.22 µm) and 5 mM EDTA (Life Technologies #AM9260G)). We then blocked Fc receptors (human TruStain FcX, BioLegend #422302) and stained leukocytes for 20-minutes at 4°C (8-colour panel: CD3 (clone OKT3), CD4 (clone OKT4), CD127 (clone A019D5), CD25 (clone M-A251), CCR7 (clone G043H7), CD45RA (clone HI100), CD38 (clone HIT2) and HLA-DR (clone L243)). After washing leukocytes were kept in cold flow buffer and filtered through a 40 µm cell strainer (Scientific Labs Supply #352340). We used a FACS-Aria IIIu or Fusion cell sorter (BD Biosciences, FACS Diva v8 software, 70 µm nozzle, sort setting "purity") to simultaneously sort 10,000 of each of the following CD4$^+$ T cell subsets - naive (CD3^{pos} CD4^{pos} CD127^{pos} CCR7^{pos} CD45RA^{pos}), effector/effector memory (EM) (CD3^{pos} CD4^{pos} CD127^{pos} CCR7^{neg} CD45RA^{neg}) and regulatory (CD3^{pos} CD4^{pos} CD25^{hi} CD127^{neg}). T cells were sorted directly into RNAse free sterile 1.5 ml screw cap tubes (ThermoFisher #11529924) containing 1 ml Trizol Reagent (ThermoFisher #15596026). Tubes were incubated for 5-minutes at room temperature and stored at -80°C. At the same time, we sorted naive T cells into flow buffer and reacquired them to check sort purity, which was above 95% for every sample analysed in this study. Flow data acquired during sorting was analysed using FlowJo v9 software.

CD4$^+$ T cell RNA-sequencing

RNA was extracted using a modified phenol-chloroform protocol (58) with 1-Bromo-3-chloropropane (Sigma-Aldrich #B62404) and Isopropanol (Acros Organics #423835000). Total RNA was quantified and assessed for quality and integrity by Bioanalyser (RNA Pico 6000 Chip, Agilent #5067-1513) - all sequenced samples had a RIN value above 8. cDNA was generated from 1 ng total RNA using the SMART-Seq v4 Ultra Low Input RNA Kit (Takara Bio #634894) and amplified using 12 cycles of PCR. Amplified cDNA was purified using Agencourt AMPure XP beads (Beckman Coulter #A63880), quantified on a Qubit Fluorometer (dsDNA HS assay kit, ThermoFisher #Q32851) and quality assessed by Bioanalyser (DNA HS Kit, Agilent #5067-4626). Libraries were then constructed from 150 pg of cDNA using the Nextera XT DNA Library Preparation Kit (Illumina #FC-131-1024) according to the manufacturer's instructions. Libraries were quantified by Qubit (dsDNA HS assay) and fragment size distribution was assessed by Bioanalyser (DNA HS Kit). Using this information, samples were combined to create equimolar library pools that were sequenced on a NextSeq 550 Illumina platform to yield 75 bp PE reads; the average number of PE reads per sample passing QC across all samples was 2.74 x 10^7.

Data analysis of CD4$^+$ T cell RNA-sequencing

Quality and content of FASTQ files were assessed using FastQC and reads were aligned to the Ensembl release 96 Homo sapiens transcript set with bowtie2 v2.2.7 (49) (parameters: —very-sensitive -p 30 —no-mixed —no-discordant —no-unal). Our median alignment rate was 66.4% after removing primer and adapter traces (SMART-Seq v4 primers, polyG, polyT and polyN) with cutadapt v1.9. The sorted, indexed bam files were then used to obtain a matrix of normalised counts for each transcript using samtools idxstats. Transcript counts were imported into the R/Bioconductor

environment (v3.6) and differential gene expression analyses (pairwise group comparisons)
performed using functions within the DESeq2 package (52). lfcShrink was applied to the output of
each comparison (type normal). Lists of differentially expressed transcripts were filtered by removing
all non-coding transcripts and retaining only those with adj p < 0.05 and fold-change > 1.5. Multiple
transcripts annotated to the same gene were consolidated by keeping the transcript with the highest
absolute fold-change. Heatmaps and circular stacked bar plots were generated using the *ggplot2*
package.

Functional gene enrichment analysis using clueGO

Lists of differentially expressed genes were imported into clueGO v2.5.7 (59, 60). ClueGO identified
significantly enriched GO terms (GO Biological Process and GO Molecular Function) associated with
these genes and placed them into a functionally organised non-redundant gene ontology network
based on the following parameters: adj p cutoff = 0.01; correction method used = Bonferroni step
down; min. GO level = 5; max. GO level = 11; number of genes = 3; min. percentage = 5.0; GO
fusion = true; sharing group percentage = 40.0; merge redundant groups with > 40.0% overlap;
kappa score threshold = 0.4; and evidence codes used [All]. Each of the functional groups was
assigned a unique colour and a network was then generated using an edge-weighted spring-
embedded layout based on kappa score. Groups were named by the leading GO term (lowest adj p
with min. GO level 5 or 6). Merged networks were constructed by inputting two lists of differentially
expressed genes. For each GO term information on what fraction of associated genes were derived
from each list was retained. Any GO term containing > 60% associated genes from a single list was
considered to be enriched in that group, otherwise GO terms were considered to be shared.

Multiplexed plasma analyte analysis

The concentration of 39 analytes was measured in plasma samples collected at baseline, during
infection, diagnosis, 6-days after drug treatment (T6) and at a memory timepoint (28- or 45-days
post-challenge). Plasma was thawed on ice and centrifuged at 1000 xg for 1-minute to remove
potential protein aggregates. We customised 4 LEGENDplex panels (BioLegend) and performed
each assay on filter plates according to the manufacturer's instructions. Samples and standards
were acquired on a LSRFortessa flow cytometer (BD Biosciences). FCS files were processed using
LEGENDplex software (version 7.1), which automatically interpolates a standard curve using the
plate-specific standards and calculates analyte concentrations for each sample. All samples from
v1040 were excluded after failing QC and downstream data analysis was performed in R v3.6. To
determine which plasma analytes varied significantly through time we used the *lme4* package to fit
a linear mixed-effects model for each analyte. All available time-points were included and models
were fitted using log2 transformed plasma analyte concentration as dependent variable, time-point
as a categorical fixed effect and volunteer as a random effect. A Kenward-Roger approximation was
used to calculate p values (using the *pbkrtest* package), which were adjusted for multiple testing
(Benjamini-Hochberg method). Results were visualised with *ggplot2* (53) and only those with at least
a 1.5 fold-change from baseline are shown. To determine which plasma analytes varied between
infections at diagnosis we used *lme4* to fit a mixed-effects model for each analyte in the form of
analyte ~ timepoint + infection_number + (1|volunteer) using log2 transformed concentrations. Time-
point and infection number were included as categorical fixed effects and volunteer as a random
effect. Linear hypothesis testing via pairwise comparisons was performed using *multcomp*'s glht

function and adjusted for multiple testing (Benjamini and Hochberg). Only analytes that were
significant in both second and third infection (versus first infection) are shown (adj p < 0.05 and fold-
change > 1.5).

Pearson correlation analysis

The fold-change of each significant plasma analyte (shown in figure 3 - supplement 1B), the number
of circulating lymphocytes and haemoglobin concentration were calculated at diagnosis or T6
(relative to baseline) according to their largest absolute fold-change. The percentage of activated
effector and regulatory $CD4^+$ T cells, the maximum parasite density and maximum core temperature
(at any time-point up to 48-hours post-treatment) were also included in the analysis. All data were
log2 transformed and Pearson correlation was performed using the corrplot function. Correlation
coefficients were then used for hierarchical clustering by Euclidean distance.

CyTOF sample acquisition

Venous blood was collected in K_2EDTA-coated vacutainers, stabilised within 30-minutes of blood
draw in whole blood preservation buffer (Cytodelics #hWBCS002) and stored at -80°C. For antibody
staining, samples were thawed at 37°C in a water bath, fixed for 15-minutes and red blood cells
lysed using the whole blood preservation kit (Cytodelics #hC002). Cells were permeabilised with
Maxpar barcode perm buffer (Fluidigm #201057) and each sample was barcoded using Cell-ID 20-
plex palladium barcodes (Fluidigm #201060). Samples were then pooled and stained with our T cell
focussed surface antibody panel (see supplementary file 3) for 30-minutes. Following washing, cells
were fixed and permeabilised with the Maxpar nuclear antigen staining buffer set (Fluidigm #201063)
and incubated with the nuclear antibody mix for 45-minutes. After washing, cells were fixed for 10-
minutes in 1.6% formaldehyde diluted in PBS (ThermoFisher #28906). Cells were then washed
again, resuspended at a concentration of 3×10^6 cells per ml in 72.5 nM Cell-ID Intercalator Ir solution
(Fluidigm #201192A) and stored overnight at 4°C. Samples were acquired the next day on a freshly
tuned Helios mass cytometer (Fluidigm, acquisition rate 300-500 events/second) using the WB
injector and 10% EQ Four Element Calibration Beads (140Ce, 151Eu, 165Ho, and 175Lu; Fluidigm
#201078).

CyTOF data analysis

The Fluidigm CyTOF software (version 6.7) generated FCS files, which were normalised (61) and
debarcoded (62) using the R package CATALYST (63). Samples were compensated using single
stained beads (64). After exclusion of normalisation beads and doublets we gated on $CD45^{pos}$ $CD3^{pos}$
T cells using the Cytobank web portal (Beckman Coulter, www.cytobank.org). We then inspected
the intensity distribution of each channel and removed channels of low variance (CD3, CD16, CD45,
CD69, CXCR5, GATA3, RORγt, TCRγδ, and Tim3). The remaining 30 markers were used for both
UMAP projections and FlowSOM clustering.

UMAP (65) was used to generate a 2D projection of this high-dimensional dataset. Here phenotypic
similarity of cells within and between populations is preserved in the Euclidean distance of the
projection. We used its R implementation in the *scater* package (66), which in turn relies on *uwot*
(github.com/jlmelville/uwot). Features were scaled to unit variance and the 15 nearest neighbours

were considered for embedding. UMAP coordinates were then exported for visualisation using *ggplot2* (53). FlowSOM (67) uses self-organising maps (SOM) to efficiently categorise cytometry data into non-overlapping cell populations and was performed using CATALYST (63) (default parameters, target: 100 clusters, 50 metaclusters). After manual inspection we merged two phenotypically similar clusters to avoid overclustering (68) and ended up with 49 discrete T cell clusters. The R/Bioconductor package *ComplexHeatmap* (69) was used to visualise T cell phenotypes; the arcsine transfomed signal intensity of each marker was independently scaled using a 0-1 transformation across all 49 clusters.

For differential cluster abundance analysis we used the workflow laid out by Nowicka *et al.* (70). FlowSOM cluster cell counts were modelled linearly with time-point as a dependent categorical variable and volunteer as a fixed effect using the *diffcyt* (71) implementation of edgeR (72). The edgeR functions automatically normalise cluster counts for the total number of cells and improve statistical power by sharing information on cluster count variance between clusters. Pairwise comparisons were performed relative to baseline, and clusters with an FDR < 0.05 and absolute fold change > 2 were deemed to vary significantly through time. We assessed differential cluster abundance independently for volunteers receiving either their first or third infection. We also assessed whether marker expression significantly varies through time in the major T cell subsets. To do this, we merged clusters of the same lineage according to their expression of CD4, CD8, CD56, Vδ2 and Vα7.2. CD4$^+$ and CD8$^+$ T cells were then split into naive, effector, effector memory and central memory T cells based on their expression of the markers CD45RA, CD45RO, CD57 and CCR7. All regulatory T cells (CD25^{hi} CD127^{neg}) were merged into a single cluster as were all double negative, gamma delta, MAIT and NK T cells. Linear models derived from the *limma* package, which is optimised for continuous data, were then used to independently assess differential marker expression relative to baseline using pairwise comparisons with moderated t-tests; a shift in median expression of at least 10% and an FDR < 0.05 were required for significance. Results were visualised using *ComplexHeatmap* (69) with row-wise z-score transformed marker intensities shown for each subset.

To analyse the T cell response to *Plasmodium vivax* data from two previously conducted clinical trials were used. In VAC069A six healthy malaria-naive adults were recruited to test the infectivity and safety of a new cryopreserved stabilate containing a novel clone of *P. vivax* (PvW1); this stabilate had been carefully prepared for use in CHMI by blood challenge (Minassian *et al.*, under review). In VAC069B three volunteers returned for a homologus re-challenge (8-months after VAC069A) and two additional malaria-naive adults received their first infection with PvW1. In both CHMI trials treatment was initiated once two diagnostic conditions were fulfilled: parasitaemia above 5,000 parasite genome copies per ml; parasitaemia above 10,000 genome copies per ml; positive thick blood smear and/or symptoms consistent with malaria. Treatment usually consisted of artemether and lumefantrine (Riamet) or atovaquone and proguanil (Malarone) if Riamet was contraindicated. Blood sampling, sample processing and CyTOF data analysis were all performed analogously to VAC063C. VAC069 was sponsored by the University of Oxford, received ethical approval from UK NHS Research Ethics Service (South Central - Hampshire A reference 18/SC/0577) and was registered on ClinicalTrials.gov (NCT03797989). The trial was conducted in line with the current version of the Declaration of Helsinki 2008 and conformed with the ICH Guidelines for Good Clinical Practice.

figure one - supplement 1

Figure 1 - supplement 1 | Lymphocyte recruitment to inflamed tissues is a shared response to the
first three infections of life. (**A**) Lymphocytes were quantified in whole blood at diagnosis and counts
were normalised to baseline measurements (taken one day before challenge). Normalised counts
are shown for each volunteer (dots) and bars show the median fold-change during first, second and
third infection. No statistically significant difference between infections was observed (Kruskal-Wallis
test p = 0.4483). (**B**) Proportion of lymphocytes, monocytes, neutrophils and eosinophils in whole
blood at baseline and diagnosis. The mean frequency is shown for each time-point and infection. In
(A-B) n = 10 (first and second infection) and n = 6 (third infection).

Figure 2 - supplement 1 | Interferon-stimulated inflammation is a shared response to the first three infections of life. (**A**) RNA-sequencing was used to identify differentially expressed genes in whole blood at diagnosis versus baseline (adj p < 0.05 and > 1.5 fold-change). Note that first, second and third infection were analysed independently. Volcano plots show all differentially expressed genes (coloured dots) and the dashed lines represent the significance/fold-change cut-offs (genes that are not significant are shown in grey). The top 10 differentially expressed genes (lowest adj p) in each infection are labelled. (**B**) The log2 fold-change of signature genes associated with interferon signaling and type I inflammation are shown at diagnosis (versus baseline) in first, second and third infection. Square brackets indicate that common gene names have been used. In (A-B) n = 10 (first infection), 9 (second infection) and 6 (third infection). v1040 was excluded from RNA-sequencing analysis in second infection because their baseline sample failed QC.

figure two – supplement 2

Figure 2 - supplement 2 I Systemic inflammation peaks at diagnosis. Mixed-effects modelling was used to identify plasma analytes that vary significantly at diagnosis across the entire dataset (all volunteers and all infections). Kenward Roger approximation was used to calculate p values and multiple test correction was performed using the Benjamini-Hochberg method (*adj p < 0.05, **adj p < 0.005, ***adj p < 0.0005). Box (median and IQR) and whisker (1.5x upper or lower IQR) plots are shown with outliers as dots. n = 9 (first and second infection) and 5 (third infection). v1040 was excluded from plasma analysis because all samples failed QC.

figure three – supplement 1

Figure 3 - supplement 1 I The acute phase response resolves 6-days after parasite clearance. (**A**) Frequency and severity of lymphopenia, anaemia and thrombocytopenia at diagnosis and T6 across the VAC063C cohort. (**B**) Mixed-effects modelling was used to identify plasma analytes that vary significantly at diagnosis and/or T6 across the entire dataset (all volunteers regardless of infection number). Kenward Roger approximation was used to calculate p values and multiple test correction was performed using the Benjamini-Hochberg method; significance (adj p < 0.05) is indicated by a coloured box and whiskers (purple at diagnosis and turquoise at T6). In (A) n = 11 (3 first infection, 2 second infection and 6 third infection) and in (B) n = 10 (3 first infection, 2 second infection and 5 third infection). v1040 was excluded from plasma analysis because all samples failed QC.

Figure 3 - supplement 2 I The transcriptional signature in whole blood at T6 does not overlap with
diagnosis. (**A**) RNA-sequencing was used to identify differentially expressed genes in whole blood
at diagnosis (left) and T6 (right) during first infection (versus baseline, adj p < 0.05 and > 1.5 fold-
change). Volcano plots show all differentially expressed genes (coloured dots) and the dashed lines
represent the significance/fold-change cut-offs (genes that are not significant are shown in grey).
The top 10 differentially expressed genes (lowest adj p) at each time-point are labelled. (**B**) Direct
pairwise comparison between T6 and diagnosis - the 5 genes with the lowest adj p value are labelled
in both directions. (**C**) Differentially expressed genes at T6 and diagnosis were combined for GO
analysis of first infection and clueGO was used to construct a merged functional gene ontology
network. Each node represents a GO term and nodes are coloured according to whether their
associated genes were majoritively (> 60%) derived from the diagnosis or T6 time-point. GO terms
that were shared between time-points are coloured grey (see methods). Seven leading GO terms
(each from a unique functional group) are labelled for each time-point. In (A-C) n = 3 (all first
infection).

figure three - supplement 3

862   **Figure 3 - supplement 3** | The acute phase response is followed by a signature of cell proliferation
863   in naive hosts. Whole blood RNA-sequencing was used to identify differentially expressed genes at
864   diagnosis and T6 (versus baseline) during first and third infection (adj $p < 0.05$ and > 1.5 fold-
865   change). The log2 fold-change of key genes associated with each phase of the cell cycle is shown.
866   n = 3 (first infection) and 6 (third infection).

figure three – supplement 4

867   **Figure 3 - supplement 4** I Gating strategy for sorting CD4+ T cells during the VAC063C trial. CD4+
868   T cell subsets were sorted *ex vivo* (within 2-hours of blood draw) into TRIzol for downstream RNA-
869   sequencing - cells with a naive, effector/effector memory (EM) and regulatory phenotype were gated
870   as shown at baseline and T6. Note that we did not use CD38 for sorting but subsequently used this
871   marker to assess the level of activation within each subset at both time-points.

A

microtubule cytoskeleton organization

oxidative phosphorylation

regulation of cell cycle
G2/M phase transition

positive regulation of intracellular transport

chromatin remodeling

regulation of cellular
biosynthetic process

protein export from nucleus

mRNA processing

ATP binding

DNA replication

mitochondrial translation

receptor ligand activity

cyclic-nucleotide-mediated signaling

B

total 345 GO terms

C

fatty acid β−oxidation

ECH1

ACADS

HADH

ACAA2

ACADM

0.5
1
1.5
log2FC

acyl CoA

acetyl CoA

TCA cycle

IDH3A
IDH3B
OGDH
SUCLG1
SDHA
SDHB
SDHD
FH
MDH1
MDH2
PDHA1
CS
IDH1
IDH2

log2FC

2
1

FADH₂/NADH

H⁺ H⁺
H⁺ H⁺

H⁺ H⁺
H⁺ H⁺

H⁺ H⁺

inner mitochondrial membrane

electron transport chain

complex I

complex II

complex III

complex IV

H⁺ gradient

NADH
dehydrogenase

succinate
dehydrogenase

cyt c reductase

cyt c oxidase

ATP synthase

% upregulated genes

figure four − supplement 1

Figure 4 - supplement 1 I Effector CD4$^+$ T cells are proliferative and metabolically reprogrammed
during first infection. (**A-B**) Genes that were differentially expressed in effector/effector memory (EM)
CD4$^+$ T cells at T6 of first infection (versus baseline, adj $p < 0.05$ and fold-change > 1.5) were used
to create a non-redundant functional gene ontology network in clueGO. Each node represents a GO
term and node size is determined by adj p. Related GO terms that share > 40% of genes are
connected by a line and organised into functional groups (each given a unique colour). The leading
GO term from each of the 13 largest groups is labelled and (B) shows their proportion of total GO
terms. The outer ring on the pie indicates whether groups were up- or downregulated (red or blue,
respectively). (**C**) Transcriptional regulation of fatty acid β-oxidation, the tricarboxylic acid (TCA)
cycle and oxidative phosphorylation (oxphos) in effector/EM CD4$^+$ T cells during first infection. The
circular bar charts show the log2 fold-change of each major enzyme involved in fatty acid β-oxidation
and the TCA cycle at T6 (shown in reaction order, clockwise). The vertical bar chart shows the
proportion of oxphos enzymatic subunits that are transcriptionally upregulated at T6 - all subunits
required to form complex I to IV in the electron transport chain and ATP synthase are shown. The
key molecules that connect these metabolic pathways are labelled. In (A-C) n = 2 for T6 and 3 for
baseline (v313 was excluded at T6 because this sample failed QC).

figure four - supplement 2

Figure 4 - supplement 2 I CD4$^+$ T cells are not anergic, exhausted or deleted in tolerised hosts. (**A-**
C) RNA-sequencing was used to identify differentially expressed genes in naive, effector / effector
memory (EM) and regulatory CD4$^+$ T cells 6-days after parasite clearance (T6 versus baseline) in
first and third infection (adj p < 0.05 and > 1.5 fold-change). Heatmaps show the log2 fold-change of
(A) transcription factors downstream of T cell receptor signaling, (B) hallmark genes indicating T cell
anergy or quiescence and (C) markers of clonal deletion. In (A-C) n = 2 or 3 for first infection (T6
and baseline, respectively) and 6 for third infection. v313 was excluded at T6 because this sample
failed QC.

figure five - supplement 1

896   **Figure 5 - supplement 1** I Phenotype of T cell clusters. Heatmap showing the normalised median
897   expression values of all markers used for clustering in each of the 49 T cell clusters. Names were
898   assigned manually using activation, lineage and memory markers to broadly categorise each T cell
899   cluster; when more than one cluster was placed into the same category (e.g. activated EM CD4)
900   clusters were given an accessory label to highlight their unique phenotype or property (e.g. T-bet[lo]).

figure five – supplement 2

Figure 5 - supplement 2 | Frequency of each CD4$^+$ T cell cluster during and after infection. Every
cluster is shown as a proportion of all CD45^{pos} CD3^{pos} T cells at each time-point. Clusters that were
differentially abundant in first and/or third infection are shown first (ordered by size, big to small) and
clusters that did not vary significantly through time are displayed thereafter (ordered by size, small
to big). Box (median and IQR) and whisker (1.5x upper or lower IQR) plots are shown (with outliers
as dots) and significance (FDR < 0.05 and > 2 fold-change) is indicated by a coloured box. n = 3
(first infection) and 6 (third infection).

cluster frequency (% total T cells)

figure five - supplement 3

Figure 5 - supplement 3 | Frequency of each CD8$^+$ T cell cluster during and after infection. Every
cluster is shown as a proportion of all CD45^{pos} CD3^{pos} T cells at each time-point. Clusters that were
significantly increased during infection are shown first followed by clusters that were significantly
decreased (ordered by size, big to small). Thereafter, clusters that did not vary significantly through
time are displayed (ordered by size, small to big). Box (median and IQR) and whisker (1.5x upper or
lower IQR) plots are shown (with outliers as dots) and significance (FDR < 0.05 and > 2 fold-change)
is indicated by a coloured box. n $= 3$ (first infection) and 6 (third infection).

cluster frequency (% total T cells)

Figure 5 - supplement 4 I Frequency of each innate-like T cell cluster during and after infection.
Every cluster is shown as a proportion of all CD45^{pos} CD3^{pos} T cells at each time-point. Clusters that
were significantly increased during infection are shown first followed by clusters that were
significantly decreased (ordered by size, big to small). Thereafter, clusters that did not vary
significantly through time are displayed (ordered by size, small to big). Box (median and IQR) and
whisker (1.5x upper or lower IQR) plots are shown (with outliers as dots) and significance (FDR <
0.05 and > 2 fold-change) is indicated by a coloured box. n = 3 (first infection) and 6 (third infection).

figure five - supplement 5

Figure 5 - supplement 5 I Differential marker expression reveals attenuation of the adaptive T cell response to re-challenge. We assessed whether marker expression significantly varies through time in all major T cell subsets. First, T cell clusters belonging to the same lineage were merged and then $CD4^+$ and $CD8^+$ T cells were split into naive, effector, effector memory (EM) and central memory (CM) subsets. Next, linear models were used to independently assess differential marker expression in each subset at each time-point (relative to baseline); a shift in median expression of at least 10% and an $FDR < 0.05$ were required for significance. Shown are all subset/marker pairs that were called as significant at T6 and data are presented as row-wise z-score marker intensities. Colour codes to the left of the heatmap indicate whether markers were differentially expressed during first infection, third infection or both infections.

activation (% lineage)

baseline | diagnosis | T6 | memory

gamma delta

MAIT

v313 v315 v320 v1039 v1040 v1061 v1068 v1075 v6032

- first infection
- third infection

figure five - supplement 6

Figure 5 - supplement 6 I Innate-like T cells are highly activated in tolerised hosts. Bar charts
display the frequency of activated (CD38^{hi} Bcl2^{lo}) gamma delta and MAIT clusters at each time-point.
Data are shown as a proportion of the entire lineage (Vδ2^{pos} for gamma delta and Vα7.2^{pos} for MAIT).
n = 3 (first infection) and 6 (third infection).

Figure 6 - supplement 1 I *Plasmodium vivax* induces tolerance after a single infection. Six healthy
malaria-naive adults were infected with *P. vivax* (clone PvW1) by direct blood challenge and three
volunteers returned for a homologous re-challenge 8-months later. These CHMI trials were called
VAC069A and VAC069B, respectively. Two additional healthy malaria-naive volunteers were
infected with PvW1 (for the first time) during VAC069B. In both trials, whole blood was preserved
within 30-minutes of blood draw at baseline, diagnosis and 6-days post-treatment (T6) - samples
were stained with a T cell focussed antibody panel and acquired on a Helios mass cytometer. After
exclusion of normalisation beads and doublets we gated on CD45^{pos} CD3^{pos} T cells for FlowSOM
clustering, which was performed independently for VAC069A and VAC069B. (**A**) Bar chart showing
the frequency of activated (CD38^{hi} Bcl2^{lo}) CD4$^+$ T cell clusters at T6. (**B**) Stacked bar chart showing
the frequency of all activated (CD38^{hi} Bcl2^{lo}) T cell clusters at T6. In (A-B) data are shown as a
proportion of all CD45^{pos} CD3^{pos} T cells and n = 8 (first infection) or 3 (second infection).

Supplementary files

Supplementary file 1 I Demographics of volunteers infected and re-challenged with *Plasmodium falciparium* (3D7); includes genetic and non-genetic variables known to influence human immune variation *in vitro*. Also shown is the parasite multiplication rate (detailed methodology for the modelling of qPCR data can be found in Minassian *et al*. (47)) and maximum core body temperature measured in each volunteer during each infection. There were no statistically significant differences between first, second and third infection (Kruskal-Wallis test, $p = 0.3287$ for parasite multiplication rate and $p = 0.9949$ for core temperature).

Supplementary file 2 I Pearson correlation coefficient and p value measuring the relationship between inflammation, coagulation, symptoms, parasites and T cell activation. These data underpin the matrix shown in figure 3C.

Supplementary file 3 I Mass cytometry antibody panel for T cell fate and function in falciparum malaria; includes information on antibody clone and heavy metal conjugate.

References

1. B. P. Goncalves *et al.*, Parasite burden and severity of malaria in Tanzanian children. *N Engl J Med* **370**, 1799-1808 (2014).
2. C. A. Moxon, M. P. Gibbins, D. McGuinness, D. A. Milner, Jr., M. Marti, New Insights into Malaria Pathogenesis. *Annu Rev Pathol* **15**, 315-343 (2020).
3. R. W. Snow, K. Marsh, New insights into the epidemiology of malaria relevant for disease control. *Br Med Bull* **54**, 293-309 (1998).
4. R. W. Snow *et al.*, Risk of severe malaria among African infants: direct evidence of clinical protection during early infancy. *J Infect Dis* **177**, 819-822 (1998).
5. D. L. Doolan, C. Dobano, J. K. Baird, Acquired immunity to malaria. *Clin Microbiol Rev* **22**, 13-36 (2009).
6. J. Tuju *et al.*, Antigenic cartography of immune responses to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). *PLoS Pathog* **15**, e1007870 (2019).
7. K. Cumnock *et al.*, Host Energy Source Is Important for Disease Tolerance to Malaria. *Curr Biol* **28**, 1635-1642 e1633 (2018).
8. S. Ramos *et al.*, Renal control of disease tolerance to malaria. *Proc Natl Acad Sci U S A* **116**, 5681-5686 (2019).
9. A. Wang *et al.*, Glucose metabolism mediates disease tolerance in cerebral malaria. *Proc Natl Acad Sci U S A* **115**, 11042-11047 (2018).
10. R. Medzhitov, D. S. Schneider, M. P. Soares, Disease tolerance as a defense strategy. *Science* **335**, 936-941 (2012).
11. T. W. Ademolue, Y. Aniweh, K. A. Kusi, G. A. Awandare, Patterns of inflammatory responses and parasite tolerance vary with malaria transmission intensity. *Malar J* **16**, 145 (2017).
12. W. Nahrendorf, A. Ivens, P. J. Spence, Inducible mechanisms of disease tolerance provide an alternative strategy of acquired immunity to malaria. *Elife* **10**, (2021).
13. K. Milne *et al.*, Mapping immune variation and var gene switching in naive hosts infected with Plasmodium falciparum. *Elife* **10**, (2021).
14. D. I. Stanisic, J. S. McCarthy, M. F. Good, Controlled Human Malaria Infection: Applications, Advances, and Challenges. *Infect Immun* **86**, (2018).
15. J. K. Baird *et al.*, Adult Javanese migrants to Indonesian Papua at high risk of severe disease caused by malaria. *Epidemiol Infect* **131**, 791-797 (2003).
16. J. K. Baird *et al.*, Age-dependent susceptibility to severe disease with primary exposure to Plasmodium falciparum. *J Infect Dis* **178**, 592-595 (1998).
17. S. J. Draper *et al.*, Malaria Vaccines: Recent Advances and New Horizons. *Cell Host Microbe* **24**, 43-56 (2018).
18. C. J. Duncan, S. J. Draper, Controlled human blood stage malaria infection: current status and potential applications. *Am J Trop Med Hyg* **86**, 561-565 (2012).
19. Q. Cheng *et al.*, Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. *Am J Trop Med Hyg* **57**, 495-500 (1997).
20. P. J. Spence *et al.*, Vector transmission regulates immune control of Plasmodium virulence. *Nature* **498**, 228-231 (2013).
21. E. Spaulding *et al.*, STING-Licensed Macrophages Prime Type I IFN Production by Plasmacytoid Dendritic Cells in the Bone Marrow during Severe Plasmodium yoelii Malaria. *PLoS Pathog* **12**, e1005975 (2016).

22.   D. Ghosh, J. S. Stumhofer, The spleen: "epicenter" in malaria infection and immunity. *J*
Leukoc Biol, (2021).

23.   C. F. Ockenhouse *et al.*, Common and divergent immune response signaling pathways
discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic
and clinically apparent malaria. *Infect Immun* **74**, 5561-5573 (2006).

24.   T. M. Tran *et al.*, Transcriptomic evidence for modulation of host inflammatory responses
during febrile Plasmodium falciparum malaria. *Sci Rep* **6**, 31291 (2016).

25.   L. Hviid *et al.*, Rapid reemergence of T cells into peripheral circulation following treatment of
severe and uncomplicated Plasmodium falciparum malaria. *Infect Immun* **65**, 4090-4093
(1997).

26.   V. H. Carpio *et al.*, T Helper Plasticity Is Orchestrated by STAT3, Bcl6, and Blimp-1 Balancing
Pathology and Protection in Malaria. *iScience* **23**, 101310 (2020).

27.   M. A. Koch *et al.*, The transcription factor T-bet controls regulatory T cell homeostasis and
function during type 1 inflammation. *Nat Immunol* **10**, 595-602 (2009).

28.   C. Y. Fonseka *et al.*, Mixed-effects association of single cells identifies an expanded effector
CD4(+) T cell subset in rheumatoid arthritis. *Sci Transl Med* **10**, (2018).

29.   H. Mattoo *et al.*, Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-
related disease. *J Allergy Clin Immunol* **138**, 825-838 (2016).

30.   K. Marsh, R. W. Snow, Host-parasite interaction and morbidity in malaria endemic areas.
Philos Trans R Soc Lond B Biol Sci **352**, 1385-1394 (1997).

31.   G. Napolitani *et al.*, Clonal analysis of Salmonella-specific effector T cells reveals serovar-
specific and cross-reactive T cell responses. *Nat Immunol* **19**, 742-754 (2018).

32.   M. F. Chughlay *et al.*, Liver Enzyme Elevations in Plasmodium falciparum Volunteer Infection
Studies: Findings and Recommendations. *Am J Trop Med Hyg* **103**, 378-393 (2020).

33.   I. J. Reuling *et al.*, Liver Injury in Uncomplicated Malaria is an Overlooked Phenomenon: An
Observational Study. *EBioMedicine* **36**, 131-139 (2018).

34.   J. Woodford, G. D. Shanks, P. Griffin, S. Chalon, J. S. McCarthy, The Dynamics of Liver
Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study.
Am J Trop Med Hyg **98**, 1113-1119 (2018).

35.   M. Dudek *et al.*, Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in
NASH. *Nature* **592**, 444-449 (2021).

36.   S. Gupta, R. W. Snow, C. A. Donnelly, K. Marsh, C. Newbold, Immunity to non-cerebral
severe malaria is acquired after one or two infections. *Nat Med* **5**, 340-343 (1999).

37.   R. S. Osii, T. D. Otto, P. Garside, F. M. Ndungu, J. M. Brewer, The Impact of Malaria
Parasites on Dendritic Cell-T Cell Interaction. *Front Immunol* **11**, 1597 (2020).

38.   J. Kim *et al.*, Innate-like Cytotoxic Function of Bystander-Activated CD8(+) T Cells Is
Associated with Liver Injury in Acute Hepatitis A. *Immunity* **48**, 161-173 e165 (2018).

39.   N. P. Weng, K. Liu, M. Catalfamo, Y. Li, P. A. Henkart, IL-15 is a growth factor and an
activator of CD8 memory T cells. *Ann N Y Acad Sci* **975**, 46-56 (2002).

40.   R. M. Welsh, L. K. Selin, No one is naive: the significance of heterologous T-cell immunity.
Nat Rev Immunol **2**, 417-426 (2002).

41.   B. M. Greenwood, Possible role of a B-cell mitogen in hypergammaglobulinaemia in malaria
and trypanosomiasis. *Lancet* **1**, 435-436 (1974).

42.   L. C. Mourao, G. P. Cardoso-Oliveira, E. M. Braga, Autoantibodies and Malaria: Where We
Stand? Insights Into Pathogenesis and Protection. *Front Cell Infect Microbiol* **10**, 262 (2020).

43. L. Deng, R. A. Mariuzza, Recognition of self-peptide-MHC complexes by autoimmune T-cell receptors. *Trends Biochem Sci* **32**, 500-508 (2007).

44. N. L. Smith *et al.*, A Conserved TCRbeta Signature Dominates a Highly Polyclonal T-Cell Expansion During the Acute Phase of a Murine Malaria Infection. *Front Immunol* **11**, 587756 (2020).

45. N. Malaria Genomic Epidemiology, Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia and Oceania. *Nat Commun* **10**, 5732 (2019).

46. E. Patin *et al.*, Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. *Nat Immunol* **19**, 302-314 (2018).

47. A. M. Minassian *et al.*, Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. *Med (N Y)* **2**, 701-719 (2021).

48. R. O. Payne *et al.*, Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. *J Infect Dis* **213**, 1743-1751 (2016).

49. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**, 357-359 (2012).

50. C. A. Harrington *et al.*, RNA-Seq of human whole blood: Evaluation of globin RNA depletion on Ribo-Zero library method. *Sci Rep* **10**, 6271 (2020).

51. H. Shin *et al.*, Variation in RNA-Seq transcriptome profiles of peripheral whole blood from healthy individuals with and without globin depletion. *PLoS One* **9**, e91041 (2014).

52. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).

53. H. Wickam, ggplot2: Elegant Graphics for Data Analysis. *Springer-Verlag New York*, (2016).

54. H. Mizuno, Y. Nakanishi, N. Ishii, A. Sarai, K. Kitada, A signature-based method for indexing cell cycle phase distribution from microarray profiles. *BMC Genomics* **10**, 137 (2009).

55. J. Pena-Diaz *et al.*, Transcription profiling during the cell cycle shows that a subset of Polycomb-targeted genes is upregulated during DNA replication. *Nucleic Acids Res* **41**, 2846-2856 (2013).

56. D. Dominguez *et al.*, A high-resolution transcriptome map of cell cycle reveals novel connections between periodic genes and cancer. *Cell Res* **26**, 946-962 (2016).

57. B. Giotti, A. Joshi, T. C. Freeman, Meta-analysis reveals conserved cell cycle transcriptional network across multiple human cell types. *BMC Genomics* **18**, 30 (2017).

58. P. Chomczynski, N. Sacchi, The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. *Nat Protoc* **1**, 581-585 (2006).

59. G. Bindea *et al.*, ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* **25**, 1091-1093 (2009).

60. B. Mlecnik *et al.*, Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. *Sci Transl Med* **6**, 228ra237 (2014).

61. R. Finck *et al.*, Normalization of mass cytometry data with bead standards. *Cytometry A* **83**, 483-494 (2013).

62. E. R. Zunder *et al.*, Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. *Nat Protoc* **10**, 316-333 (2015).

63. H. Crowell, V. Zanotelli, S. Chevrier, M. Robinson, CATALYST: Cytometry dATa anALYSis Tools. *R/Bioconductor* **version 1.14.0**, (2020).

64. S. Chevrier *et al.*, Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry. *Cell Syst* **6**, 612-620 e615 (2018).

65. L. McInnes, J. Healy, J. Melville, UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. *arXiv:1802.03426*, (2020).

66. D. J. McCarthy, K. R. Campbell, A. T. Lun, Q. F. Wills, Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. *Bioinformatics* **33**, 1179-1186 (2017).

67. S. Van Gassen *et al.*, FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. *Cytometry A* **87**, 636-645 (2015).

68. Y. Saeys, S. Van Gassen, B. Lambrecht, Response to Orlova et al. "Science not art: statistically sound methods for identifying subsets in multi-dimensional flow and mass cytometry data sets". *Nat Rev Immunol* **18**, 78 (2017).

69. Z. Gu, R. Eils, M. Schlesner, Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* **32**, 2847-2849 (2016).

70. M. Nowicka *et al.*, CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. *F1000Res* **6**, 748 (2017).

71. L. M. Weber, M. Nowicka, C. Soneson, M. D. Robinson, diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering. *Commun Biol* **2**, 183 (2019).

72. M. D. Robinson, D. J. McCarthy, G. K. Smyth, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-140 (2010).